Insider Buying: Syros Pharmaceuticals Inc (NASDAQ:SYRS) Insider Buys 9,879 Shares of Stock

Share on StockTwits

Syros Pharmaceuticals Inc (NASDAQ:SYRS) insider Jeremy P. Springhorn purchased 9,879 shares of the business’s stock in a transaction on Monday, November 11th. The shares were purchased at an average price of $4.99 per share, with a total value of $49,296.21. Following the completion of the purchase, the insider now owns 24,879 shares in the company, valued at $124,146.21. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NASDAQ:SYRS opened at $5.24 on Thursday. The stock has a 50 day moving average of $7.30 and a 200 day moving average of $7.96. The company has a market cap of $211.77 million, a PE ratio of -2.74 and a beta of 1.49. The company has a current ratio of 8.11, a quick ratio of 8.11 and a debt-to-equity ratio of 0.15. Syros Pharmaceuticals Inc has a 12-month low of $4.88 and a 12-month high of $11.93.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.01. Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. The company had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.43 million. Equities research analysts predict that Syros Pharmaceuticals Inc will post -1.88 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can lifted its holdings in Syros Pharmaceuticals by 11,319.2% in the 2nd quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after purchasing an additional 2,943 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Syros Pharmaceuticals by 863.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock worth $28,000 after purchasing an additional 2,409 shares in the last quarter. A.R.T. Advisors LLC purchased a new position in Syros Pharmaceuticals in the 2nd quarter worth approximately $119,000. Susquehanna International Group LLP purchased a new position in Syros Pharmaceuticals in the 2nd quarter worth approximately $133,000. Finally, Algert Global LLC purchased a new position in Syros Pharmaceuticals in the 2nd quarter worth approximately $166,000. 93.14% of the stock is currently owned by institutional investors.

A number of equities research analysts have issued reports on SYRS shares. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Tuesday. Zacks Investment Research upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research note on Wednesday, October 23rd. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, October 18th. HC Wainwright reiterated a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday. Finally, ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $13.46.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

See Also: Which market index is the best?

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Capital City Bank Group, Inc.  Director Acquires $43,410.00 in Stock
Capital City Bank Group, Inc. Director Acquires $43,410.00 in Stock
Raymond James  CEO Sells $280,273.62 in Stock
Raymond James CEO Sells $280,273.62 in Stock
Brokerages Set Triumph Bancorp Inc  Target Price at $34.50
Brokerages Set Triumph Bancorp Inc Target Price at $34.50
Hudson Pacific Properties Inc  Receives $40.75 Average Price Target from Analysts
Hudson Pacific Properties Inc Receives $40.75 Average Price Target from Analysts
Lendingblock Price Reaches $0.0017
Lendingblock Price Reaches $0.0017
Photon Achieves Market Capitalization of $83,292.00
Photon Achieves Market Capitalization of $83,292.00


© 2006-2019 Ticker Report